Secondary Logo

Journal Logo

Letters to the Editor

IgG From HIV-1–Exposed Seronegative and HIV-1–Infected Subjects Differently Modulates IFN-γ Production by Thymic T and B Cells

da Ressureição Sgnotto, Fábio BsCa; Souza Santos, Ludimila BsCb,c; Rodrigues de Sousa, Thamires BsCb; Feitosa de Lima, Josenilson PhDb; Mara da Silva Oliveira, Luanda PhDb; Saeed Sanabani, Sabri PhDd; José da Silva Duarte, Alberto PhD, MDb,e; Russo Victor, Jefferson PhDb,c

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: December 15, 2019 - Volume 82 - Issue 5 - p e56-e60
doi: 10.1097/QAI.0000000000002182

To the Editors:

Interferon-gamma (IFN-γ), a pleiotropic cytokine, which is mainly produced by activated lymphocytes, has long been considered to play a pivotal role in mediating host–pathogen interactions. Understanding how cells produce IFN-γ is thus important key to eventually elucidate the mechanisms involved in the pathogenesis and therapy.1 Specifically, in HIV-1 infection, increased plasma levels of IFN-γ have been linked to lower CD4+ cell count recovery during antiretroviral therapy,2 a parameter of great clinical importance for such patients.

Our group has investigated the effect of IgG molecules in mediating the modulation of lymphocyte function.3–11 For instance, our previous studies in humans have demonstrated that IgG molecules can exert their regulatory and/or modulatory function by interacting with lymphocytes during their maturation process in primary lymphoid organs and that their effective immunological profile is dependent on the donor's immune status. More precisely, we have shown that IgG antibodies from atopic donors and atopic dermatitis patients are associated with inhibition of IFN-γ production and induction of IL-10 and IL-17 production, respectively, by the thymic TCD4 and TCD8 cells.12,13 In our previous studies, we found that IgG could exert a regulatory function not only on the production of IL-17 by thymic murine and human γδ T cells14 but also on the production of both IFN-γ and IL-10 by the thymic human γδ T cells.15 The recent study by de Oliveira et al14 has demonstrated the capability of IgG to interact with the membrane of thymic murine and human γδ T cells that generally do not express FcγRs (IgG receptors). This finding reinforces the hypothesis that IgG can interact with the immature cells by its variable sites and, thus, would possibly recognize the clonal receptors of these cells and consequently modulate their functional properties according to its IgG repertoire.16

Taken together, these pieces of evidence would strongly suggest that murine and human IgG might be a mediator of modulatory effects in several disorders. Here, we sought to investigate this possibility further in other diseases characterized by immunological modulation.

There is scarce evidence in the literature to explain the biological properties in some individuals who escape HIV infection despite being relatedly exposed and who have no genetic traits to justify this resistance (HIV-1–exposed seronegative individuals—ESN).17–19 Although these properties are certainly related to the immunological characteristics of the exposed individuals,20 there is little evidence in the literature requiring further evaluation.

Here, we used a brief and unprecedented approach to evaluate whether the IgG from ESN individuals can exert some modulatory effect on the production of IFN-γ, which is widely known as an extremely important cytokine for CTL- and NK-cell–mediated immune responses. To this end, we performed a well-standardized in vitro protocol of human thymocytes maturation in the presence of IgG12–15 to investigate whether the major human lymphocyte populations that produce IFN-γ (TCD4, TCD8, and γδ T and B cells) could be modulated according to the IgG donor's immune status in HIV infection or exposition.

METHODS

To obtain purified IgG from our analysis groups, HIV-1–serodiscordant couples were recruited from the outpatient clinic at the Emílio Ribas Infectious Diseases Institute in São Paulo, from the Ambulatory Service (ADEE/3002) of the Department of Secondary Immunodeficiency Clinic of the Clinical Hospital, University of São Paulo Medical School (HC/FMUSP). ESN individuals (n = 20), HIV-1–infected partners of ESN individuals (n = 20), and healthy non–HIV-exposed and -uninfected individuals (n = 20) were enrolled in this study. This study was approved by the São Paulo University Institutional Use Committee (CAPPesq no 0683/09), and informed consent was obtained from all subjects. All experimental protocols were performed in accordance with relevant guidelines and regulations approved by the Ethics Committee of this institution.

Additional information of the study population is listed in Table 1, Supplemental Digital Content, http://links.lww.com/QAI/B379. Couples reported mean relationship duration of 13 years with a single partner and participation in 5 episodes of unprotected sexual intercourse at a frequency of 3–4 times per month. The subjects were seronegative at the studied time point and were genetically evaluated to confirm that they do not carry the most relevant genetic mutation of HIV-1 resistance (CCR5-Delta 32 homozygous genotype). All HIV-1–infected individuals included in this analysis were on the virally effective antiretroviral therapy soon after their diagnosis was made. Two blood samples were obtained from each individual through venipuncture and placed in tubes without anticoagulants. After the blood samples were centrifuged, the serum was fractionated, pooled, and stored at −80°C until IgG purification. As an additional control, we used the commercially purified IgG (IVIg—Endobulin Baxter, AT). Additional method description can be found online in the Supplementary Material, Supplemental Digital Content, http://links.lww.com/QAI/B379.

RESULTS

First, we provided evidence that the frequency of IgG subclasses in all purified IgG pools was similar between groups (see Figure S1, Supplemental Digital Content, http://links.lww.com/QAI/B379). Next, we evaluated whether the culture conditions used in this study could influence the frequency and viability of the thymic lymphocytes populations. As depicted in Figure 1, no alterations were found in the frequency and viability of γδ T cells after 7 days of culture (Fig. 1A), B cells (Fig. 1B), TCD4 cells (Fig. 1C), and TCD8 cells (Fig. 1D). Then, cultures were performed to evaluate the intracellular production of IFN-γ in the studied populations. These results strongly suggest that IgG molecules from ESN individuals have the potential to induce the production of IFN-γ in γδ T (Fig. 1E) and B cells (Fig. 1F) compared with all other culture conditions. As presented in Figure 1G, H, we observed a similar effect mediated by IgG from HIV-1–infected individuals with the induction of IFN-γ in TCD4 and TCD8 cells compared with all culture conditions.

FIGURE 1.
FIGURE 1.:
Frequency, viability, and the effect of purified HIV-1–infected and ESN IgG on thymic γδ T, B, TDC4, and TCD8 cells. Thymocytes (n = 14) were evaluated after 7 days in culture in RPMI medium supplemented with FCS in the absence (mock) or presence of 100 µg/mL of IVIg or IgG purified from healthy individuals (HI), HIV-1–infected individuals (HIV-1) or HIV-1–exposed seronegative individuals. The frequencies and viability of γδ T (A), B (B), TCD4 (C), and TCD8 (D) cells were demonstrated. Intracellular IFN-γ production is demonstrated in γδ T (E), B (F), TCD4 (G), and TCD8 (H) cells. The results are illustrated by box-and-whisker plots with 25th percentiles, and the Tukey method was used to plot outliers; *P ≤ 0.05 when compared with mock, IVIg, HI, and HIV-1 conditions; **P ≤ 0.05 when compared with mock, IVIg, HI, and ESN conditions.

Altogether, our results demonstrate that IgG from ESN individuals induces IFN-γ production in thymic γδ T and B cells, while IgG from HIV-1–infected individuals induces IFN-γ production in thymic TCD4 and TCD8 cells.

DISCUSSION

Since 1994, The IFN-γ production has been linked to the activation of TCD8 cells and the control of HIV infection in 199421; however, no comparative study to determine the importance of each lymphoid populations as a main source of IFN-γ has been made since. Thus, it is difficult to discuss the role of the differential modulation observed in response to IgG from ESN or HIV-1–infected individuals in terms of possible immunomodulatory consequences.

The previous study by Yin et al22 reported that γδ T cells predominantly produce IFN-γ on activation, even in the presence of IL-4 or high GATA-3 expression. Our current study provided evidence that the IgG molecules from ESN individuals have the potential to induce the production of IFN-γ in thymic γδ T compared with the effect mediated by IgG from HIV-1–infected individuals and controls. More recently, it has been demonstrated that γδ T cells have the potential to target and clear autologous HIV reservoirs on latency reversal, thus indicating that they can effectively be used as immunotherapeutic agents in future strategies that involve elimination of HIV-1.23 Therefore, our observations suggest that IgG from ESN individuals can favor the activation of thymic γδ T cells, thus hindering HIV infection; however, this is still a hypothetical possibility, with a need for well-designed future study to confirm.

Our results also indicate the capacity of the IgG from ESN individuals to induce IFN-γ production in thymic B cells compared with IgG from HIV-1–infected individuals. Concerning this analysis, we did not evaluate further functional alterations, which may have been induced in thymic B cells. However, as these cells are responsible for the production of antibodies that exert inhibitory or even protective functions against HIV-1 infection,24 additional evaluations need to be undertaken to elucidate this issue. Furthermore, we did not observe any difference in the frequency of IgG subclasses between the evaluated groups. This finding is particularly important because B cells express FcγRs that can differentially interact with IgG subclasses and suggests that the differential effect of each IgG is mediated by its variable region.

The observation that IgG from HIV-1–infected individuals induces IFN-γ in TCD4 cells results in an interesting corroboration with the literature. For example, the study by Teixeira et al25 revealed that the increase of the poor TCD4 cell observed in some HIV-1–infected patients can be caused by the failure of thymic TCD4 cell production. These results were further supported in a later study by Gazzola et al.26 Consistent with the previous findings, we believe that the augmentation of IFN-γ production in thymic TCD4 may indicate an exacerbated activation of these cells, thereby favoring apoptosis and consequently failing thymic TCD4 cell production.

Finally, we observed that IgG from HIV-1–infected individuals also induces IFN-γ in TCD8 cells. As discussed above, it is well known that the TCD8 cells play a pivotal role in controlling HIV infection,21 and we showed in the current study that the IgG produced in response to HIV-1 infection could mediate the activation of these cells in thymic tissue as observed by the augmented IFN-γ production. Of note, the induction of IFN-γ production in TCD8 cells has been associated with increased suppressive effect in viral replication.27 Based on this fact, we assumed that the augmented IFN-γ production observed in this study might be related to the control of HIV dissemination in infected individuals.

Transposing these in vitro results to the in vivo conditions, we suggest that the IgG repertoire naturally produced by the ESN group differs from the HIV-1–infected individuals, and this could result in differential patterns of IFN-γ production. This difference can exert some role in the exposed uninfected individuals, but it is important to highlight that the low exposition to HIV-1 in terms of low viral load is a feature of our ESN individuals' group.

Although we have not elucidated the mechanisms underlying our observations, we assume that the IgG might directly interact with the clonal receptors expressed by lymphocytes during its maturation in thymus.16 Also, because of technical limitations, we were unable to elucidate the precise mechanism of the IgG effect; we demonstrate that IgG antibodies produced by ESN or HIV-1–infected individuals have potential to exert divergent modulatory effects on the production of IFN-γ by thymic lymphocytes. We hope that our observations will contribute to the generation of future hypothesis and open field to assess the role of IgG in resistance or response to HIV-1 infection.

ACKNOWLEDGMENTS

The authors thank Dr. Luciana Bento de Souza for the technical support in preparing the human thymocyte suspensions.

REFERENCES

1. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): exploring its implications in infectious diseases. Biomol Concepts. 2018;9:64–79.
2. Watanabe D, Uehira T, Suzuki S, et al. Clinical characteristics of HIV-1-infected patients with high levels of plasma interferon-γ: a multicenter observational study. BMC Infect Dis. 2019;19:11.
3. de Oliveira MG, Oliveira LdM, de Lima Lira AA, et al. Preconception allergen sensitization can induce B10 cells in offspring: a potential main role for maternal IgG. Allergy Asthma Clin Immunol. 2017;13:22.
4. de Oliveira MG, Lira AAL, Sgnotto FDR, et al. Preconception immunization can modulate intracellular Th2 cytokine profile in offspring: in vivo influence of interleukin 10 and B/T cell collaboration. Cent Eur J Immunol. 2018;43:378–388.
5. Victor JR. Influence of maternal immunization with allergens on the thymic maturation of lymphocytes with regulatory potential in children: a broad field for further exploration. J Immunol Res. 2014;2014:780386.
6. Lira AAL, de-Oliveira MG, Inoue AHS, et al. Preconceptional allergen immunization can induce offspring IL-17 secreting B cells (B17): do they share similarities with regulatory B10 cells? Allergol Immunopathol (Madr). 2018;46:454–459.
7. Victor JR, Fusaro AE, Duarte AJ, et al. Preconception maternal immunization to dust mite inhibits the type I hypersensitivity response of offspring. J Allergy Clin Immunol. 2003;111:269–277.
8. Rigato PO, Fusaro AE, Victor JR, et al. Maternal immunization to modulate the development of allergic response and pathogen infections. Immunotherapy. 2009;1:141–156.
9. Victor JR, Muniz BP, Fusaro AE, et al. Maternal immunization with ovalbumin prevents neonatal allergy development and up-regulates inhibitory receptor Fc gamma RIIB expression on B cells. BMC Immunol. 2010;11:11.
10. Muniz BP, Victor JR, Oliveira LdM, et al. Tolerogenic microenvironment in neonatal period induced by maternal immunization with ovalbumin. Immunobiology. 2014;219:377–384.
11. de Lima Lira AA, de Oliveira MG, de Oliveira LM, et al. Maternal immunization with ovalbumin or dermatophagoides pteronyssinus has opposing effects on Fc gamma RIIb expression on offspring B cells. Allergy Asthma Clin Immunol. 2014;10:47.
12. Sgnotto FDR, Oliveira MG, Lira AAL, et al. Low doses of IgG from atopic individuals can modulate in vitro IFN-γ production by human intra-thymic TCD4 and TCD8 cells: an IVIg comparative approach. Hum Vaccin Immunother. 2017;13:1563–1572.
13. Sgnotto FDR, de Oliveira MG, Lira AAL, et al. IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intrathymic TCD4 and TCD8 cells. Int J Dermatol. 2018;57:434–440.
14. de Oliveira MG, de Lima Lira AA, da Ressureição Sgnotto F, et al. Maternal IgG impairs the maturation of offspring intrathymic IL-17-producing γδT cells: implications for murine and human allergies. Clin Exp Allergy. 2019;49:1000–1012.
15. Santos LS, Sgnotto FDR, Inoue AHS, et al. IgG from non-atopic individuals induces in vitro IFN-γ and IL-10 production by human intra-thymic γδT cells: a comparison with atopic IgG and IVIg. Arch Immunol Ther Exp (Warsz). 2019;67:263–270.
16. Victor JR. Allergen-specific IgG as a mediator of allergy inhibition: lessons from mother to child. Hum Vaccin Immunother. 2017;13:507–513.
17. Lima JF, Oliveira LMS, Pereira NZ, et al. Polyfunctional natural killer cells with a low activation profile in response to Toll-like receptor 3 activation in HIV-1-exposed seronegative subjects. Sci Rep. 2017;7:524.
18. Osawe S, Okpokoro E, Datiri R, et al. Development of a prospective cohort of HIV exposed sero-negative (HESN) individuals in Jos Nigeria. BMC Infect Dis. 2016;16:352.
19. Rahman S, Rabbani R, Wachihi C, et al. Mucosal serpin A1 and A3 levels in HIV highly exposed sero-negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders. Am J Reprod Immunol. 2013;69:64–72.
20. Fenizia C, Rossignol JF, Clerici M, et al. Genetic and immune determinants of immune activation in HIV-exposed seronegative individuals and their role in protection against HIV infection. Infect Genet Evol. 2018;66:325–334.
21. Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–6110.
22. Yin Z, Zhang DH, Welte T, et al. Dominance of IL-12 over IL-4 in gamma delta T cell differentiation leads to default production of IFN-gamma: failure to down-regulate IL-12 receptor beta 2-chain expression. J Immunol. 2000;164:3056–3064.
23. Garrido C, Clohosey ML, Whitworth CP, et al. γδ T cells: an immunotherapeutic approach for HIV cure strategies. JCI Insight. 2018;3:1–12.
24. Agazio AE, Pelanda R, Torres RM. Silencing of TLM B cells by chronic HIV infection. Nat Immunol. 2018;19:902–903.
25. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15:1749–1756.
26. Gazzola L, Tincati C, Bellistrì GM, et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009;48:328–337.
27. Pannus P, Adams P, Willems E, et al. In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients. AIDS. 2019;33:387–398.

Supplemental Digital Content

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.